Investor Presentation • Apr 21, 2022
Investor Presentation
Open in ViewerOpens in native device viewer
Annual Report 2021 April 21, 2022
This presentation (the "Presentation") has been produced by Atlantic Sapphire ASA (the "Company") exclusively for information purposes. This Presentation has not been approved, reviewed or registered with any public authority or stock exchange. This Presentation is not a prospectus and does not contain the same level of information as a prospectus. This Presentation is strictly confidential and may not be disclosed, in whole or in part, or summarized or otherwise reproduced, distributed or referred to, in whole or in part, without prior written consent of the Company. To the best of the knowledge of the Company and its Board of Directors, the information contained in this Presentation is in all material respect in accordance with the facts as of the date hereof, and contains no material omissions likely to affect its import.
This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates or intends to operate. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. None of the Company or any of its subsidiary undertakings or any such person's officers or employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. The Company assumes no obligation to update any forward-looking statements or to conform these forward-looking statements to our actual results. Furthermore, information about past performance given in this Presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor any of its parent or subsidiary undertakings or any such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. Actual experience may differ, and those differences can be material.
By reviewing this Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the businesses of the Company. This Presentation must be read in conjunction with the recent financial reports of the Company and the disclosures therein, as well as other public disclosures made by the Company. The distribution of this Presentation may in certain jurisdictions be restricted by law. Persons in possession of this Presentation are required to inform themselves about, and to observe, any such restrictions. No action has been taken or will be taken in any jurisdiction by the Company that would permit the possession or distribution of this Presentation in any country or jurisdiction where specific action for that purpose is required.
This Presentation does not in itself constitute an offer to sell or form part of, and should not be construed as, an offer or invitation for the sale or subscription of, or a solicitation of an offer to buy or subscribe for, any shares or other securities in any jurisdiction, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.
This Presentation must be read in conjunction with the stock exchange release to which it is attached.
By reviewing this Presentation, you agree to be bound by the foregoing limitations.
This Presentation speaks as of April 21, 2022. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation. This Presentation shall be governed by Norwegian law, and any disputes relating to hereto is subject to the sole and exclusive jurisdiction of Norwegian courts, with Oslo District Court as legal venue.
1 FIFF: The feed fish inclusion factor estimates the combined fishmeal and fish oil concentration of the feed on a dry-weight basis relative to the wild fish.
|
| (USD 1,000) | Note | 2021 | 2020 |
|---|---|---|---|
| Revenue | 3 | 16,851 | 6,270 |
| Expenses | |||
| Cost of materials | 5,15 | 65,607 | 18,169 |
| Fair value adjustment on biological assets | 5 | (1.429) | 9,478 |
| Salary and personnel costs | 6, 18, 20 | 10.584 | 7.448 |
| Other operating expenses | 4,7,8 | 24,572 | 11,025 |
| Impairment of non-current assets | 9.23 | 34,754 | |
| Depreciation and amortization | $\overline{9}$ | 15.056 | 6,745 |
| Total expenses | 149,144 | 52,865 | |
| Operating loss | (132, 293) | (46, 595) | |
| Finance income | 10 | 3.362 | 889 |
| Finance expense | 10.19 | (3.847) | (9.487) |
| Loss before income tax benefit | (132, 778) | (55, 193) | |
| Income tax benefit | 11 | ||
| Net loss | (132, 778) | (55, 193) | |
| Earnings per share: | |||
| Basic earnings per share | (1.53) | (0.74) | |
| Diluted earnings per share | (1.53) | (0.74) |
| (USD 1,000) | 2021 | 2020 | |
|---|---|---|---|
| 2021 Consolidated Statements of Financial Position | ASSETS | ||
| Non-current assets | |||
| ▪ Reduction in PP&E related to USD34.8m impairment of the |
Property, plant, and equipment, net | 264,449 | 257,080 |
| Other | 3,384 | 4,205 | |
| Denmark asset | Total non-current assets | 267,833 | 261,285 |
| ▪ Gain to be recorded on the insurance settlement amount |
Current assets | ||
| Prepaid and other current assets | 1,593 | 1,573 | |
| Inventories, net | 6,590 | 2,713 | |
| Biological assets | 16,795 | 24,610 | |
| ▪ Total 2021 capital expenditures of USD57.5m |
Trade and other receivables, net Restricted cash |
1,449 468 |
1,869 386 |
| ▪ Largely tied to US Phase 2 construction |
Cash | 17,012 | 28,523 |
| Total current assets | 43,907 | 59,674 | |
| ▪ USD9m for US Phase 1 capex, USD2m in Denmark capex |
TOTAL ASSETS | 311,740 | 320,959 |
| EQUITY AND LIABILITIES | |||
| Equity | |||
| ▪ NIBD as of December 31, 2021: USD33m |
Total equity | 239,556 | 255,459 |
| ▪ USD1.1m "PPP loan" forgiven in H2 2021 |
Non-current liabilities | ||
| Borrowings (non-current) | 50,000 | 51,156 | |
| ▪ USD20m RCF facility undrawn |
Lease liability (non-current) | 2,842 | 3,091 |
| Total non-current liabilities | 52,842 | 54,247 | |
| Current liabilities | |||
| Lease liability (current) | 324 | 482 | |
| Trade and other payables | 19,018 | 10,771 | |
| Total current liabilities | 19,342 | 11,253 | |
| TOTAL EQUITY AND LIABILITIES | 311,740 | 320,959 |
2021 Financials Reflect Ramp-Up Of US Phase 1 Production and Phase 2 Construction
| Fish farming | ||||
|---|---|---|---|---|
| Year ended 31 December 2021 (USD 1,000) |
Denmark | US | Other and eliminations |
Consolidated |
| Revenue from sale of salmon EBITDA EBITDA, pre-fair value adjustment on biological assets EBITDA, adjusted* Pre-tax loss |
3,560 (43, 461) (45,062) (10, 308) (48, 076) |
13,291 (71, 403) (71, 231) (71, 231) (89, 528) |
(2, 373) (2, 373) (2, 373) 4,826 |
16,851 (117, 237) (118, 666) (83, 912) (132, 778) |
| Total assets Total liabilities |
1,488 40,045 |
298,617 154,216 |
11,635 (122, 077) |
311,740 72,184 |
| Depreciation and amortization Interest income Interest expense Impairment of non-current assets Capital expenditures |
2,899 1,716 34,754 1,908 |
12,157 1,388 7,356 55,549 |
1,974 (5, 225) |
15,056 3,362 3,847 34,754 57,457 |
| Cash flows from operating activities Cash flows from investing activities Cash flows from financing activities |
(3, 386) (2,674) 5,198 |
(63, 725) (55, 238) 112,805 |
(765) 1 (3, 144) |
(67, 876) (57, 911) 114,859 |
| 2021: Adjusted US Phase 1 fixed cost base walk1 |
USDm |
|---|---|
| Total expenses | 84.7 |
| External chiller rental | (11.0) |
| Extraordinary mortality | (7.7) |
| 2021 feed cost | (13.1) |
| Adj. 2021 US "fixed cash cost" excl. feed |
52.9 |
1 Cost on an EBITDA level excluding extraordinary costs in 2021 and feed cost
Risk of mortality events reduced both in size and frequency:
|
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.